full comment requir non-u analyst conflict disclosur
pleas click link
downgrad product declin
roll thru upcycl upgrad outperform
think move part view post manag discuss
share expect track peer
review expand distribut reach
phar phrom phix pharmedium issu continu troubl
pend sympazan launch set pave way lead product liberv next year
put soft softgel report weak maintain guid
theori practic focu deal close go-forward strategi
revenu miss focu turn investor day
underli posit in-lin soft guid
mani surpris first result
high-dos valid move forward fl pembro ritux
vyxeo weak continu overshadow solid xyrem result anticip pullback
in-lin lower slower time take-out
oi low-qual lower target slightli maintain sector perform
face competit product lower target maintain sector perform
transit take hold
lay foundat outperform
late-cycl tailwind point organ revenu growth acceler
solid result guid
price prior day market close estimate unless otherwis note
new horizon
note boston bu tour hear commerci pipelin updat
result gener line expect increas distribut
note boston bu tour dive gmg updat pnh/renal strategi
result mix product guidanc low end cost high end
abstract garnet orr updat data come updat
becton dickinson compani
arri preview seem like time
preview cheat sheet
preview cheat sheet
solid integr track announc ny deal look attract
underli busi remain strong multipl headwind weigh ep guid
climb toward apex spring continu upsid opportun
til new year
stay right track
hard swallow colorado result
investor day highlight focu profit growth new market
strong guid deal track
solid quarter valuat compel
 of daili summari
clear clearbrook
updat result
nt readout clarifi promis potenti posit cf portfolio
recap model updat
judg rule requir licens sep chip supplier
steadi improv busi help off-set global growth worri
look share price advanc
updat estim charl river impact
better expect wood
model updat updat model reflect loan sale
kap good lay foundat stone synergi
find research
insight www rbcinsightresearch com global research destin web contact capit market sale
repres access global research site use ipad app research
valu usd unless otherwis note
valu usd unless otherwis note
downgrad product declin
downgrad freeport under-perform sector perform given
premium valuat ahead expect declin product
oper risk associ transit open-pit underground
mine grasberg integr risk associ inalum becom
new partner price target support
lower rate under-perform sector
perform financi estim expect declin
grasberg mine transit underground block cave mine
share trade premium ev/ebitda p/nav valuat histor
averag copper produc peer believ premium
warrant given risk associ on-going oper ownership
transit grasberg
challeng see grasberg includ delay start-up
dmlz mine potenti start-up delay grasberg block cave deal
local labor forc transit underground mine
loss rio tinto strong technic partner develop work
relationship inalum new partner
report revenue/ep vs street expect
dec-qtr guid well street
midpoint vs street
need sep-qtr result came mix vs street
estim dec-qtr guid well consensu expect due
memori headwind inventori adjust key custom well
increment headwind us regulatori action chines
memori player exhibit degre flexibl cost structur
manag guidanc suggest signific de-lever effect ep dec-qtr
thing could sequenti start improv start logic/foundri
spend pick see share gain ga deliveri subsystem think
materi memori relat wfe risk remain investor like remain
sidelin see sign memori relat headwind subsid posit
data point custom net/net grew wfe upcycl
think signific risk could see sharper wfe declin
next year semicap specif memori spend declin lower
rate sector perform revis price target ep
estim
valu usd unless otherwis note
roll thru upcycl upgrad outperform
usac remain focus post-acquisit integr effort deploy idl
fleet maxim roa think strong market fundament along synergi
cdm merger provid path de-lev grow coverag closer
toward beyond fundament like persist strong
view upgrad usac sector perform outperform current
maintain price target upgrad sector perform outperform
usac growth stori stay intact strong market fundament combin
integr cdm provid usac path improv distribut coverag closer
beyond energi transfer current ownership usac
unit may continu overhang stock think continu cash flow
growth along improv leverag drive usac valuat multipl
higher appli target multipl ebitda arriv us
price target upgrad usac outperform rate
valu usd unless otherwis note
think move part view post manag discuss
report adjust result well street last night first earn
releas sinc deal result provid detail seen sinc earli
discuss manag last night said pressur continu
come wors expect sever move part understand
normal earn level lower ebitda near-term focu remain
sever move part number work
new ebitda move lower million
million million million focu revenu like pick given
margin compress short-term durat dynam given remedi
limit recent launch activ decreas product report
revenu million ebitda million came well street
million million like bring near-term re-set though
temporari spend weigh ebitda specif gross
margin well larg higher remedi spend
product shut-down million medium/long-term realist
profit level still revenu miss disappoint
competit natur due price prior year
share expect track peer
valu usd unless otherwis note
valu usd unless otherwis note
reiter sector perform rate alamo gold reduc price target
given declin near-term free cash flow follow revis
model post result alamo share trade discount intermedi
peer believ discount like persist reflect concern around modest
near-term free cash flow catalyst recent challeng young-davidson
modest free cash flow forecast next year
believ alamo gener modest free cash flow spot price
next year depend time new project believ limit near-
term free cash flow like screen well within environ short
invest horizon littl toler oper misstep
spot metal price forecast averag sustain free cash flow
howev period free cash flow forecast averag
neg free cash flow anticip new project
capit includ remain kirazli product agi
dagi lynn lake
investor frustrat around perform young-davidson continu
grow deferr lower mine tie-in higher guid cost
follow reduct full year guid product young-davidson
earlier year
level investor frustrat appear evid perform
alamo share under-perform broader gold miner index
last month
price target lower
lower price target previous reflect impact higher
guid cost deferr lower mine tie-in young-davidson
model updat result
review expand distribut reach
oper ep beat expect fia sale match estim
competit environ remain intens though enhanc
term product encouragingli ad one larg bank distributor
near-term think share could driven updat potenti
estim chang revis oper ep estim
larg reflect ep beat includ favor
impact annual actuari review oper ep estim
driven upwardli revis net invest incom
assumpt pt fine-tun repres
multipl estim book valu ex aoci incorpor
probabl acquisit premium
american equiti invest life report oper ep
vs estim consensu report ep includ
after-tax favor impact compani annual actuari review
exclud impact actuari review oper ep closer
favor benefit greater expect prepay incom
valu usd unless otherwis note
valu usd unless otherwis note
overhedg think normal oper ep roughli
math still consensu estim
fia sale in-lin estim addit one larg bank distributor
encourag posit substanti improv new money yield
given manag leeway maintain competit term across
product line introduc assetshield product
independ agent channel look think encourag
compani ad one larg bank distributor quarter
phar phrom phix pharmedium issu continu troubl
report in-lin provid disappoint initi guidanc
challeng pharmedium continu compound maintain sector perform
rate share
need know report in-lin result today provid
initi guidanc street troubl pharmedium
challeng core busi continu weigh outlook report
ep ahead street
reduc ep estim low end guidanc
 maintain sector perform rate share trim
price target reflect revis ep estim
pend sympazan launch set pave way lead product liberv next
aqst report came detail commerci updat near-term
launch sympazan importantli launch set lay import commerci
groundwork lead product liberv whose expect launch next year remain
on-track follow discuss manag remain confid
potenti meaning upsid strateg transform take root reiter
outperform rais price target
aqst set hit key commerci mileston immin launch
sympazan clobazam oral solubl film first launch one
compani proprietari product background aqst on-going
strateg transform refer initi report valid technolog
platform de-risk catalyst-heavi initi outperform specul risk
importantli sympazan launch enabl aqst build
commerci infrastructur ahead next year expect launch lead product
liberv remain biggest valu driver model sympazan
receiv final fda approv last week commerci avail expect
third week novemb initi sale team consist sale
valu usd unless otherwis note
rep region director target pediatr neurologist epileptologist
high overlap liberv wac price larg in-lin
expect made chang model remov
risk adjust rais price target
third consecut quarter report ebitda outpac
street estim accompani bump guidanc revis
guidanc suggest sequenti declin ebitda round
attribut one-tim channel inventori reduct benefit
busi long run balanc view bhc remain unchang
segment mix revenu came modestli ahead rbccm
consensu drastic varianc ebitda
report ahead estim
front consensu out-performance top line attribut us
diversifi lesser degre derm compar revenu
came expect diversifi derm higher margin
segment result stronger gross margin slightli lower opex contribut
ebitda strength
gross-to-net benefit help salix derm sustain salix
derm busi benefit improv realiz net price part
sustain anoth portion provid short-term boost
result due re-bas accrual medic dermatolog busi
volum substanti y/i nearli off-set net price
benefit segment organ basi howev management flag
benefit came short-term accrual impact note
derm revenu would revert back level reaffirm view
derm busi yet reach stabl state may take
least anoth quarter two bottom
put soft softgel report weak maintain guid
report soft result weak softgel segment up-front
invest biolog specialti drug deliveri segment think
issu caus miss larg transitori near term
financi target still in-reach
need know soft quarter led weak softgel biolog
segment think issu softgel transitori invest
biolog power larg part cash softgel enabl reach
long-term growth target organ revenu growth organ
valu usd unless otherwis note
valu usd unless otherwis note
valu usd unless otherwis note
theori practic focu deal close go-forward strategi
report solid result upsid help lower tax interest
expens focu call aetna transact deal
expect close thanksgiv synergi target revis
need know report ep modestli ahead
street help lower interest expens lower tax rate
increas ep estim estim
maintain outperform rate share
compani remain one best idea increas target price
reflect revis pro forma ep estim
revenu miss focu turn investor day
report disappoint revenu quarter especi digit growth slow
better-than-expect ep cost synergi tax rate quarter revenu
shortfal led manag reduc revenu guidanc
result report revenu adjust ep
compar estim street
respect revenu decreas y/i fxn deceler last
quarter ep beat driven lower-than-expect tax rate
revenu shortfal quarter total compani revenu miss estim
manag call shortfal rel
estim digit contract take longer ramp execut
issu applic mainten busi would attribut
remaind revenu miss rel estim greater-than-
guidanc revenu reduc ep increas manag reduc
midpoint revenu guidanc quarter
shortfal higher increment fx headwind chang
ramp digit contract increas midpoint ep guid
increas ep estim reduc target price quarter
increas adjust ep estim maintain
ep estim given continu revenu growth pressur
reduc target price-to-earnings ev/ebitda multipl point
therefor reduc target price
valu usd unless otherwis note
valu usd unless otherwis note
adjust ep estim ev/ebitda
ebitda estim
underli posit in-lin soft guid
outperform-r emerson initi ep guidanc rang fell
consensu includ healthi level conservatism/caut due
escal us-china trade war emerson first multi-industri name issu
offici guidanc under-promised/over-deliv
organ growth outlook impress high-end appear
appropri china-slowing-risk reflect low-end
dose conservat bake guidanc due us-china
trade war listen ceo dave farr earn call becam
evid emerson below-expect organ growth ep
guidanc rang includ prudent level conservat due on-going us-
china trade war mr farr clarifi low-end total compani
organ growth forecast assum trade war tension
worsen chines govern cut back invest next year far
sign worst-cas scenario play agre
caution warrant also mind emerson unenvi
posit first multi-industri name issu guidanc
first pack much less visibl work said given
ep guidanc fell consensu midpoint
view stock bp under-perform vs peer rel
contain pocket optim includ trail organ order growth
septemb target net neutral price/cost roadmap toward
upsid case ep believ offici bless
emerson analyst meet
anoth strong improv fundament quarter growth
acceler margin expans also rais outlook maintain
sector perform increas pt note present
clean rais result revenu grew y/i tad
street slightli upsid
marketplac segment adjust ebitda margin also
came rbc/street due upsid improv
oper effici narrow guidanc growth
increas revenu growth ebitda margin guid
fundi improv acceler gmv revenu
growth ebitda margin expans rank high crucial combo
spectrum among net small cap name revenu growth
ebitda margin best among small cap name
guid impli fundament trend sustain
valu usd unless otherwis note
valu usd unless otherwis note
mani surpris first result
first quarterli print stand-alone compani predict messi organ
growth solid though guidanc impli deceler margin
compress result diesel/ga mix shift occur like persist
strateg poorli posit bev financi leverag high
hook asbesto payment reiter under-perform pt drop
bottom line organ growth solid quarter saw margin
compress result higher gasolin mix expect mix dynam
well higher cost invest lower volum vs manag
guidanc weigh margin go forward
review solid organ revenu growth y/i solid detail show
lv gasolin product y/i organ lv diesel cv y/i
aftermarket y/i howev stronger growth lower margin gasolin
turbo drove gm contract adj ebitda ex-hedg
impli guidanc indic slowdown organ growth
rbce attribut lower product volum particularli
china sale howev seem manag think
in-line industri forecast continu believ ih
estim show china high
conserv europ vs ih flat anoth key region
sale impli ebitda believ impli ebitda
margin midpoint sharp deceler vs ex-
hedg despit sequenti higher sale midpoint
report modest materi rais guidanc
fundament trend remain larg consist tho book came
expect due fx shift annual contract monthli soften
china estim larg unchang roll valuat forward pt
nudg reiter outperform
result revenu y/i organ ahead
rbc/street revenu upsid came host
presenc segment fundament trend larg consist
consist y/i organ growth vs ebitda margin larg y/i
street grow y/i ex-fx larg due fx head
wind shift annual contract monthli soften china
strong arpu came y/i rise custom base -- total
custom grew y/i reach q/q slightli ahead vs
rbc/street vs
tweak estim pt revenu estim larg unchang
ufcf goe adjust ebitda goe
roll forward valuat framework
pt base averag ev/ebitda multipl
adjust ebitda ev/ufcf context continu see
consist organ grower
high-dos valid move forward fl pembro ritux
sinc decis focu effort develop last month
imdz made notabl progress re-priorit freed capit fund
oper exist cash vs guid last abstract
add new support potenti late-lin
fl registr trial slate begin management detail plan
initi combo trial rituxan line fl continu see
imdz under-valued trade cash see opportun appreci
upcom trial initi data readout next year adjust price
target model updates/refin
valu usd unless otherwis note
market data gbp financi data gbp
recent releas abstract add new support potenti
late-lin fl registr trial slate begin
management detail plan initi combo trial rituxan line fl
registr trial line fl still track
begin first data releas
adjust price target model updates/refin
squabbl minutia guidanc miss point share
trade time ep forecast that whether
guidanc includ ten million dispos gain
uncertainti long term trajectori profit ngp world remain
posit note think imperi brand credibl strategi vape
look us win argument whether e-vapour heat
burn product offer great opportun concentr effort
former nonetheless although evolut ngp categori still
rel earli stage think see consist
view burgeon ngp busi boost sale risk erod long
term profit function expect heighten competit
intens vape compar high margin cigarett busi
requir revenu invest akin brand consum
categori consequ lower margin
updat estim result new division
account disclosur forecast organ revenu growth
